Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

122 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA; IL-1RA Sepsis Syndrome Study Group. Fisher CJ Jr, et al. Crit Care Med. 1994 Jan;22(1):12-21. doi: 10.1097/00003246-199401000-00008. Crit Care Med. 1994. PMID: 8124953 Clinical Trial.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Bernard GR, et al. Among authors: fisher cj jr. N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001. N Engl J Med. 2001. PMID: 11236773 Clinical Trial.
122 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page